Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 571-582

  Awasthi, Niranjan ^a,b   Schwarz, Margaret A ^a   Schwarz, Roderich E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Docetaxel; Doxorubicin; EMAP II; Gemcitabine; Pancreatic cancer

Indexed keywords

DOCETAXEL; DOXORUBICIN; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; GEMCITABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DOXORUBICIN; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; TAXOIDS; TETRAZOLIUM SALTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054697777     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1514-7     Document Type: Article

References (38)

1. N Awasthi MA Schwarz V Verma C Cappiello RE Schwarz 2009 Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling Lab Invest 89 38 46 19002109 10.1038/labinvest.2008.106 1:CAS:528:DC%2BD1MXhtVKntw%3D%3D
2. AC Berger HR Alexander G Tang PS Wu SM Hewitt E Turner E Kruger WD Figg A Grove E Kohn D Stern SK Libutti 2000 Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis Microvasc Res 60 70 80 10873516 10.1006/mvre.2000.2249 1:CAS:528:DC%2BD3cXktlSntbo%3D
3. AC Berger HR Alexander PC Wu G Tang MF Gnant A Mixon ES Turner SK Libutti 2000 Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II) Cytokine 12 992 1000 10880244 10.1006/cyto.2000.0687 1:CAS:528:DC%2BD3cXksV2msLY%3D
4. AM Bergman VW Ruiz van Haperen G Veerman CM Kuiper GJ Peters 1996 Synergistic interaction between cisplatin and gemcitabine in vitro Clin Cancer Res 2 521 530 9816199 1:CAS:528:DyaK28XitVymu7Y%3D
5. JD Berlin P Catalano JP Thomas JW Kugler DG Haller AB Benson 3rd 2002 Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 3270 3275 12149301 10.1200/JCO.2002.11.149 1:CAS:528:DC%2BD38XmsF2rs74%3D
6. S Boeck T Hoehler G Seipelt R Mahlberg A Wein A Hochhaus HP Boeck B Schmid E Kettner M Stauch F Lordick Y Ko M Geissler K Schoppmeyer G Kojouharoff A Golf S Neugebauer V Heinemann 2008 Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer Ann Oncol 19 340 347 17962204 10.1093/annonc/ mdm467 1:STN:280:DC%2BD1c%2FotlemtQ%3D%3D
7. SR Bramhall J Schulz J Nemunaitis PD Brown M Baillet JA Buckels 2002 A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 161 167 12107836 10.1038/sj.bjc. 6600446 1:CAS:528:DC%2BD38XltFeksLw%3D
8. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D
9. L Crippa A Gasparri A Sacchi E Ferrero F Curnis A Corti 2008 Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha Cancer Res 68 1154 1161 18281491 10.1158/0008-5472.CAN-07-2085 1:CAS:528: DC%2BD1cXhvFemur8%3D
10. T Dragovich H Burris 3rd P Loehrer DD Von Hoff S Chow S Stratton S Green Y Obregon I Alvarez M Gordon 2008 Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial Am J Clin Oncol 31 157 162 18391600 10.1097/COC.0b013e31815878c9 1:CAS:528:DC%2BD1cXltVGksLo%3D
11. A Duffy J Kortmansky GK Schwartz M Capanu S Puleio B Minsky L Saltz DP Kelsen EM O'Reilly 2008 A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma Ann Oncol 19 86 91 17878176 10.1093/annonc/mdm441 1:STN:280:DC%2BD1c%2FgtVakug%3D%3D
12. AJ Hayes LY Li ME Lippman 2000 Anti-vascular therapy: a new approach to cancer treatment West J Med 172 39 42 18751215 10.1136/ewjm.172.1.39 1:STN:280:DC%2BC3cnjtlKqsw%3D%3D
13. V Heinemann D Quietzsch F Gieseler M Gonnermann H Schonekas A Rost H Neuhaus C Haag M Clemens B Heinrich U Vehling-Kaiser M Fuchs D Fleckenstein W Gesierich D Uthgenannt H Einsele A Holstege A Hinke A Schalhorn R Wilkowski 2006 Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946 3952 16921047 10.1200/JCO.2005.05.1490 1:CAS:528:DC%2BD28Xps1Sit78%3D
14. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
15. AH Ko E Dito B Schillinger AP Venook Z Xu EK Bergsland D Wong J Scott J Hwang MA Tempero 2008 A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 26 463 471 18379729 10.1007/s10637-008-9127-2 1:CAS:528:DC%2BD1cXhtVSku7fI
16. H Konno T Tanaka I Matsuda T Kanai Y Maruo N Nishino S Nakamura S Baba 1995 Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer Int J Cancer 61 268 271 7535757 10.1002/ijc.2910610221 1:CAS:528:DyaK2MXlsVCmtLk%3D
17. F Kratz A Warnecke B Schmid DE Chung M Gitzel 2006 Prodrugs of anthracyclines in cancer chemotherapy Curr Med Chem 13 477 523 16515518 10.2174/092986706776055751 1:CAS:528:DC%2BD28Xit1Klu7s%3D
18. MH Kulke MA Tempero D Niedzwiecki DR Hollis HL Kindler M Cusnir PC Enzinger SM Gorsch RM Goldberg RJ Mayer 2009 Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904 J Clin Oncol 27 5506 5512 19858396 10.1200/JCO.2009.22.1309 1:CAS:528:DC%2BC3cXhtVWitrY%3D
19. R Lenzi S Yalcin DB Evans JL Abbruzzese 2002 Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy Cancer Invest 20 464 472 12094541 10.1081/CNV-120002146 1:CAS:528:DC%2BD38Xls1eit7w%3D
20. C Louvet R Labianca P Hammel G Lledo MG Zampino T Andre A Zaniboni M Ducreux E Aitini J Taieb R Faroux C Lepere A de Gramont Giscad Gercor 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509 3516 15908661 10.1200/JCO.2005.06.023 1:CAS:528:DC%2BD2MXlsVyhsrg%3D
21. Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP, European Organisation for R, Treatment of Cancer Gastrointestinal G (2005) Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 23:9250-9256
22. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D
23. AG Reznikov LV Chaykovskaya LI Polyakova AI Kornelyuk 2007 Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model Exp Oncol 29 267 271 18199981 1:CAS:528:DC%2BD1cXivVyjtb8%3D
24. CM Rocha Lima MR Green R Rotche WH Miller Jr. GM Jeffrey LA Cisar A Morganti N Orlando G Gruia LL Miller 2004 Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776 3783 15365074 10.1200/JCO.2004.12.082 1:CAS:528:DC%2BD2cXhtVCitb%2FO
25. MW Saif 2007 Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007 JOP 8 365 373 17625289
26. H Satoh H Ishikawa M Fujimoto M Fujiwara YT Yamashita T Yazawa M Ohtsuka S Hasegawa H Kamma 1998 Angiocytotoxic therapy in human non-small cell lung cancer cell lines-advantage of combined effects of TNP-470 and SN-38 Acta Oncol 37 85 90 9572659 10.1080/028418698423221 1:STN:280:DyaK1c3jt1eksA%3D%3D
27. MA Schwarz J Kandel J Brett J Li J Hayward RE Schwarz O Chappey JL Wautier J Chabot P Lo Gerfo D Stern 1999 Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells J Exp Med 190 341 354 10430623 10.1084/jem.190.3.341 1:CAS:528:DyaK1MXkvFarsrk%3D
28. MA Schwarz F Zhang S Gebb V Starnes D Warburton 2000 Endothelial monocyte activating polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis Mech Dev 95 123 132 10906456 10.1016/S0925-4773(00) 00361-0 1:CAS:528:DC%2BD3cXkvFSntLY%3D
29. MA Schwarz H Zheng J Liu S Corbett RE Schwarz 2005 Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin Exp Cell Res 311 229 239 16248999 10.1016/j.yexcr.2005.09.008 1:CAS:528:DC%2BD2MXht1ensrnP
30. RE Schwarz N Awasthi S Konduri D Cafasso MA Schwarz 2010 EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer Ann Surg Oncol 17 1442 1452 20041350 10.1245/s10434-009-0879-5
31. RE Schwarz N Awasthi S Konduri L Caldwell D Cafasso MA Schwarz 2010 Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation Cancer Biol Ther 9 632 639 20212356 10.4161/cbt.9.8.11265 1:CAS:528:DC%2BC3cXhtlKgtrfI
32. RE Schwarz S Konduri N Awasthi D Cafasso MA Schwarz 2009 An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer Surgery 146 241 249 19628080 10.1016/j.surg.2009. 04.015
33. RE Schwarz TM McCarty EA Peralta DJ Diamond JD Ellenhorn 1999 An orthotopic in vivo model of human pancreatic cancer Surgery 126 562 567 10486610 10.1016/S0039-6060(99)70099-1 1:STN:280:DyaK1Mvhs1Sltg%3D%3D
34. RE Schwarz MA Schwarz 2004 In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II J Surg Res 120 64 72 15172191 10.1016/j.jss.2003.10.005 1:CAS:528:DC%2BD2cXksVemsLk%3D
35. AT Tandle M Calvani B Uranchimeg D Zahavi G Melillo SK Libutti 2009 Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome Exp Cell Res 315 1850 1859 19362550 10.1016/j.yexcr.2009.03.021 1:CAS:528:DC%2BD1MXms1Oqurs%3D
36. AT Tandle C Mazzanti HR Alexander DD Roberts SK Libutti 2005 Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells Cytokine 30 347 358 15935955 10.1016/j.cyto.2005.01.020 1:CAS:528:DC%2BD2MXltFWltr8%3D
37. RT Tong Y Boucher SV Kozin F Winkler DJ Hicklin RK Jain 2004 Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 3731 3736 15172975 10.1158/0008-5472.CAN-04-0074 1:CAS:528:DC%2BD2cXksVKgur8%3D
38. H Xie YX Xue LB Liu YH Liu 2010 Endothelial-monocyte-activating polypeptide II increases blood-tumor barrier permeability by down-regulating the expression levels of tight junction associated proteins Brain Res 1319 13 20 20083091 10.1016/j.brainres.2010.01.023 1:CAS:528:DC%2BC3cXitlWqtbs%3D